Posted On: 12/30/2014 9:06:23 AM
Post# of 30015
Eli Lilly and Company and AstraZeneca, who previously partnered to study an investigational treatment for Alzheimer’s disease, have announced the enrollment of the first patient in the study, called AMARANTH[/u]. The Phase II/III study aims to evaluate the safety and efficacy of oral beta secretase cleaving enzyme (BACE) inhibitor, AZD3293
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)